2 growth stars set to beat the FTSE 100

These two companies appear to have relatively low valuations given their growth prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finding shares which offer high growth prospects is not particularly challenging. Even when the outlook for the global economy is decidedly uncertain, it is still possible to find a long list of companies with double-digit earnings growth forecasts. However, finding such companies while they offer a wide margin of safety via a low valuation can prove to be much more challenging. Here are two stocks that appear to do just that, and which have the potential to beat the FTSE 100.

Strong performance

Thursday’s trading update from private healthcare group Mediclinic (LSE: MDC) shows that its current strategy is working well. Its largest platforms in Switzerland and South Africa, as well as its Dubai business, all performed in line with expectations in 2017. While its Abu Dhabi business was negatively impacted by regulatory change as well as operational difficulties, this was already priced into the company’s valuation. As such, its shares moved over 3.5% higher on the day of release.

Mediclinic is rightly focused on stabilising its underperformance in the Middle East. It remains optimistic about the long-term growth opportunities which the region offers. However, the reality is that it may take some time to turn around the disappointing performance in Abu Dhabi. As such, a downgrade to forecasts cannot be ruled out over the next couple of years.

Still, Mediclinic is expected to record a rise in its earnings of 23% in the current year, followed by growth of 14% next year. Since it trades on a price-to-earnings growth (PEG) ratio of 1.1, its shares seem to offer a sufficiently wide margin of safety to merit investment. While risk may be relatively high, the potential rewards on offer could be much higher than those of the FTSE 100.

Improving investor sentiment

Since the start of the year, the share price of specialist behavioural health services company Cambian (LSE: CMBN) has risen by 21%. This indicates that investor sentiment is improving and could continue to do so over the medium term.

Although Cambian is due to report a fall in its bottom line of 53% for the 2016 financial year, its upbeat growth outlook could lead to further capital gains for its investors. For example, its earnings are forecast to rise by 35% this year and by a further 20% next year. This could prompt further improvements to investor sentiment. Despite this positive outlook, the company’s shares trade on a PEG ratio of 0.9, which indicates there is scope for further capital gains over the medium term.

Certainly, Cambian’s track record of growth is relatively unstable. This means that its shares could be volatile over the coming months. However, there appears to be scope for it to outperform the FTSE 100 – especially while it trades at a relatively high level which is close to an all-time high.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

1 Warren Buffett stock I’m buying now

Coca-Cola is the fourth-largest holding in Warren Buffett’s Berkshire Hathaway. I’ll explain why I’m following Buffett and buying more.

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

I bought 4,403 Lloyds shares in June and 4,856 in September. Here’s what they’re worth now

Harvey Jones thought he was bagging a FTSE 100 bargain when he bought Lloyds shares on two occasions last year.…

Read more »

Young woman holding up three fingers
Investing Articles

I’m itching to buy these 3 hidden FTSE gems in a Stocks and Shares ISA

Harvey Jones is keen to add these three FTSE 100 companies to his Stocks and Shares ISA before April. Only…

Read more »

Close up of a group of friends enjoying a movie in the cinema
Investing Articles

How I’d try and turn just £1 a day into a fabulous £54,485 passive income for life

By investing small, regular sums in FTSE 100 shares I can potentially generate a huge passive income stream. It won't…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’d aim for a million buying under a dozen shares

Christopher Ruane explains why less could be more when it comes to building a share portfolio if he wants to…

Read more »

Investing Articles

Rolls-Royce shares are up over 1,000% since 2020! Am I too late to buy?

Rolls-Royce shares now cost over tenfold what they did in the firm's 2020 rights issue. Our writer thinks they may…

Read more »

Investing Articles

1 top UK growth stock for my tech portfolio in 2024

Up 30% in just one year, this growth stock looks positioned to continue on the path of substantial gains, according…

Read more »

Buffett at the BRK AGM
Investing Articles

I’d follow Warren Buffett to target effortless passive income

Warren Buffett knows a thing or two about building passive income streams. By learning from the Sage of Omaha, so…

Read more »